Skip to content
Screener

Scholar Rock SRRK RD Expense Srk181 — Research And Development Expense

Other product segments

Apitegromab
$22.95M-17.9%
RD Expense Srk439
$3.76M+46.0%
Early Research
$1.61M-27.7%

Similar metrics at other companies

Tango Therapeutics logo
TNGXPersonnel-Related Expenses-RD — Research And Development Expense
$12.93M-6.6%
Tango Therapeutics logo
TNGXTNG260Direct Program Expenses-RD — Research And Development Expense
$2.01M+16.1%
Tango Therapeutics logo
TNGXTNG456Direct Program Expenses-RD — Research And Development Expense
$2.06M+55.8%
Tango Therapeutics logo
TNGXTNG908Direct Program Expenses-RD — Research And Development Expense
$581K-66.1%
Tango Therapeutics logo
TNGXTNG961Direct Program Expenses-RD — Research And Development Expense
$408K-81.6%
Tango Therapeutics logo
TNGXDiscovery Direct Program Expenses-RD — Research And Development Expense
$1.87M-60.0%

Other financials

Income statement

See full
Revenue-
Operating income-$108.9M+2.9%
Net income-$109.9M+0.1%
EPS (diluted)-$0.84+14.3%

Balance sheet

See full
Cash & equivalents$437.1M+186%
Total debt$203.8M+231%
Total equity$253.8M+8.8%
Total assets$523.5M+54.0%

Cash flow

See full
Operating cash flow-$70.3M+8.6%
CapEx$1.0K-99.5%
Free cash flow-$70.3M+8.9%

Valuation

See full
Market cap$5.74B+92.7%
Enterprise value$5.5B+90.9%

Profitability

See full
Operating margin-231.8%
Net margin-236.9%
FCF margin-309.1%

Returns & leverage

See full
Return on equity-167.8%-4.1pp
Debt / equity0.8×+0.5×
Current ratio+0.7×

Where this comes from

Reported directly by Scholar Rock in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Scholar Rock’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:20 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336732
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Operating expenses:
Employee related expense(1)$37,445$32,484$74,971$55,422
External R&D expense - apitegromab22,94827,95643,20947,257
External R&D expense - SRK-1819792451,902
External R&D expense - SRK-4393,7602,5755,5196,854
External R&D expense - Early research and other1,6102,2272,8203,682
External expense - G&A16,59714,95232,72923,895
Other segment items(2)6,5736,27313,08211,531

Item 1. Financial Statements

FAQ

What is Scholar Rock's RD expense srk181 — research and development expense?
Scholar Rock (SRRK) reported RD expense srk181 — research and development expense of $9K in Q2 2026.
How has Scholar Rock's RD expense srk181 — research and development expense changed year-over-year?
Scholar Rock's RD expense srk181 — research and development expense decreased by 98.9% year-over-year, from $792K to $9K.
What does RD expense srk181 — research and development expense mean?
This metric represents the total operating costs directly attributable to the research and development activities for the SRK-181 product candidate. It captures the investment intensity required to advance this specific therapeutic program through preclinical and clinical development stages. Monitoring this expense helps investors assess the company's capital allocation strategy and the progress of its pipeline toward potential regulatory milestones.

Ask your AI about Scholar Rock's rd expense srk181 — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude